Charles River Laboratories International, Inc. · NYSE:CRL

Charles River Laboratories International — Q1 2026 Earnings Presentation

10 slides from Charles River Laboratories International's earnings presentation, 2026

  1. Slide 1: 1Q26 Regulation G Financial Reconciliations & Appendix

    1Q26 Regulation G Financial Reconciliations & Appendix © 2026 Charles River Laboratories International, Inc.

  2. Slide 2: Reconciliation of GAAP to Non-GAAP Selected Business Segment Information

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP TO NON-GAAP SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED) (1) (in thousands, except percentages) Three Months Ended March 28, 2026 March 29, 2025 Research Models and Services Revenue $ 208,367 $ 213,073 Operating income 49,773

  3. Slide 3: Reconciliation of GAAP to Non-GAAP Segment Information (continued)

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP TO NON-GAAP SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED) (1) (in thousands, except percentages) Three Months Ended March 28, 2026 March 29, 2025 CONTINUED FROM PREVIOUS SLIDE Unallocated Corporate Overhead $ (80,590) $ (54,26

  4. Slide 4: Reconciliation of GAAP Earnings (Loss) to Non-GAAP Earnings

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (1) RECONCILIATION OF GAAP EARNINGS (LOSS) TO NON-GAAP EARNINGS (UNAUDITED) (in thousands, except per share data) Three Months Ended March 28, 2026 March 29, 2025 Net income (loss) available to Charles River Laboratories International, Inc. common share

  5. Slide 5: Reconciliation of GAAP Revenue Growth to Non-GAAP Organic Revenue Growth

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP REVENUE GROWTH (1) TO NON-GAAP REVENUE GROWTH, ORGANIC (UNAUDITED) Three Months Ended March 28, 2026 Total CRL RMS Segment DSA Segment MS Segment Revenue growth, reported 1.2 % (2.2)% 0.7 % 6.8 % (Increase) decrease due to foreign

  6. Slide 6: Reconciliation of GAAP to Non-GAAP Revenue and EPS Guidance

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP TO NON-GAAP REVENUE AND EARNINGS PER SHARE (EPS) Guidance for the Twelve Months Ended December 26, 2026E 2026 GUIDANCE (1) CURRENT PRIOR Revenue growth/(decrease), reported (5.5)% - (4.0)% (5.0)% - (3.5)% Less: Contribution from a

  7. Slide 7: Reconciliation of GAAP Tax Rate to Non-GAAP Tax Rate

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP TAX RATE TO NON-GAAP TAX RATE (UNAUDITED) (1) (in thousands) Three Months Ended March 28, 2026 March 29, 2025 Income (loss) before income taxes & noncontrolling interests $ (29,942) $ 35,978 Add back: Amortization related to acqui

  8. Slide 8: Reconciliation of Gross/Net Leverage Ratio, Including GAAP Net Income to Adjusted EBITDA

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GROSS/NET LEVERAGE RATIO, INCLUDING GAAP NET INCOME TO ADJUSTED EBITDA (UNAUDITED) (1) (dollars in thousands, except for per share data) March 28, 2026 December 27, 2025 December 28, 2024 December 30, 2023 December 31, 2022 December 25

  9. Slide 9: Reconciliation of Free Cash Flow (Non-GAAP)

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF FREE CASH FLOW (NON-GAAP) (UNAUDITED) (1) (in thousands) Three Months Ended 2026 Guidance March 28, 2026 March 29, 2025 FYE December 26, 2026E Net cash provided by operating activities $ 41,077 $ 171,697 $575,000-$600,000 Less: Capital

  10. Slide 10: © 2026 Charles River Laboratories International, Inc.

    © 2026 Charles River Laboratories International, Inc.

Charles River Laboratories International — Q1 2026 Earnings Presentation on 6ix